New Delhi, June 2 -- Shares of Balaxi Pharmaceuticals witnessed a sharp surge on Monday, June 2, even as the company reported a weaker set of numbers for the quarter ended March 2025 (Q4 FY25). The stock, which belongs to the small-cap category and trades below Rs.100, jumped as much as 14.5 percent during intra-day trade to hit a high of Rs.57.24 on the NSE.

In Q4 FY25, the pharmaceutical company reported a widened net loss of Rs.117.85 lakh, compared to a net loss of Rs.57.52 lakh in the same quarter last year, reflecting continued margin and revenue pressure. Total income during the quarter stood at Rs.996.98 lakh, representing a steep year-on-year decline of 37.9 percent from Rs.1,606.86 lakh posted in Q4 FY24.

Sequentially, Balaxi ...